ArticleBJUI compass2026
Preoperative predictors of adverse pathology and recurrence-free survival for patients with renal masses.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Our objective was to develop algorithms to predict adverse pathology (AP) and recurrence-free survival (RFS) for patients with renal tumours primarily based on multifaceted analysis of preoperative CT imaging. Patients/Methods: Seven hundred forty-eight patients with non-metastatic renal tumours managed with definitive surgery at Cleveland Clinic (2011-2014) were retrospectively evaluated (median follow-up 9.1 years). All patients underwent contrast-enhanced CT and parenchymal volume analysis using semi-automated software. A variety of conventional radiological features were evaluated in addition to parenchymal volume replacement (PVR) due to invasive tumour growth, using the contralateral kidney as a control. Adverse pathology (AP) was defined as stage ≥pT3a, grade 3/4 or sarcomatoid/rhabdoid features. Multivariable logistic regression and Cox proportional hazards regression analyses were used to develop predictive models. Results: Overall, 339/748 patients (45%) had AP, which significantly associated with reduced RFS. On univariable analysis, tumour-size, degree of vascularity, heterogeneity, irregular contour, sinus margin irregularity, necrosis, non-cystic tumour and increased PVR significantly associated with AP. On multivariable logistic regression, male sex, R.E.N.A.L. Nearness, heterogeneity, necrosis, sinus margin irregularity and PVR ≥ 25% independently associated with AP. Multivariable analysis indicated that tumour size, heterogeneity, necrosis, PVR ≥ 25% and tumour-related symptoms significantly associated with reduced RFS. Models for AP and RFS at 3, 5 and 10 years showed area under the curve (AUC) values of 0.81 and 0.84-0.86, respectively. Conclusions: These findings confirm that radiological features and PVR are associated with AP and reduced RFS after definitive renal cancer surgery. Our predictive models are entirely based on preoperative parameters and may improve patient counselling and occasionally preclude the need for renal mass biopsy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.